VivAer: A Correlation Between Symptom Scores and Objective Findings

Inclusion Criteria: * Adults 18 years and older seeking treatment for nasal obstruction and willing to undergo an office-based procedure. * Nasal obstruction, defined as ≥60 by the NOSE scale. * The nasal valve is the primary or significant contributor to the subject's nasal obstruction as determined by the investigator, based on clinical presentation, physical examination, or nasal endoscopy. * Subjects has symptomatic improvement with use of external or internal nasal dilators, Q-Tip or curette test (manual intranasal lateralization), or the Cottle Maneuver (manual lateral retraction of the cheek). * Subject experienced minimal symptomatic improvement after the four-week fluticasone steroid nasal spray regimen. Exclusion Criteria: * Prior surgery to the nasal valve, rhinoplasty, septoplasty, inferior turbinate reduction or other surgical nasal procedures within the past 12 months. * Severe and/or chronic sinusitis, recurrent sinusitis, or allergies leading to nasal obstruction and currently requiring oral corticosteroid therapy. * Severe case of any of the following; septal deviation, turbinate hypertrophy, polyps, or ptotic nasal tip believed to be the primary contributor to the subject's nasal obstruction symptoms and warranting surgical intervention. * Known or suspected allergies or contraindications to the anesthetic agents and/or antibiotic medications to be used during the study procedure session. * Known or suspected pregnancy, or lactation. * Other medical conditions that the investigator believed would predispose subject to poor wound healing or increased surgical risk.